Drug Trial Radar · NCT01061151
Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
Last checked: Nov 19, 2026Latest source record: Feb 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,747
Actual
Start
Mar 1, 2011
Primary completion
Sep 30, 2016
Study completion Sep 30, 2016
Sponsor
- Sponsor type
- NIH
- First posted
- Feb 2, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to examine, in an integrated and comprehensive fashion, three critical questions currently facing HIV-infected pregnant and postpartum women and their infants: 1. What is the optimal intervention for the prevention of antepartum and intrapartum transmission of HIV? 2. What is the optimal intervention for the prevention of postpartum transmission in breastfeeding (BF) infants? 3. What is the optimal intervention for the preservation of maternal health after the risk period for prevention of mother-to-child-transmission ends (either at delivery or cessation of BF)? The overall PROMISE protocol had three separate interventional components to address each of these three questions and was conducted at locations in Africa and other parts of the world. Due to variations in the standard of care for HIV-infected pregnant and postpartum women and their infants at different sites, not all of these questions were relevant. Therefore, two separate versions of the PROMISE protocol were developed, each containing only the relevant components. The 1077BF protocol was used at sites where the standard method of infant feeding was breastfeeding, whereas the 1077FF protocol was used at sites where the standard method of infant feeding was formula feeding. The analyses were collapsed across the two protocol versions, and therefore the summaries contain the results of the 1077BF and/or the 1077FF protocols.
Conditions
- HIV Infections
Interventions
Zidovudine (ZDV)Drug
300 mg twice daily
Nevirapine (NVP): Antepartum MothersDrug
200 mg at onset of labor
Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tailDrug
200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Lamivudine-Zidovudine (3TC-ZDV)Drug
150 mg/300 mg twice daily
Lopinavir-ritonavir (LPV-RTV)Drug
400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])Drug
200 mg/300 mg
Nevirapine (NVP): Infant short-courseDrug
Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
Nevirapine (NVP): Infant extendedDrug
Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
No InterventionOther
Women registered before/during labor received the full Antepartum Arm A regimen. Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail.
Discontinue triple ARVsOther
ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
Continue triple ARVsOther
Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Antepartum Component: Number of Confirmed Infant HIV InfectionsTime frame: Measured at birth or Week 1 study visit
- Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse EventsTime frame: Measured through the Week 1 postpartum study visit
- Antepartum Component: Number of Mothers With Obstetrical ComplicationsTime frame: Measured through the Week 1 postpartum study visit
- Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)Time frame: Measured at birth
- Postpartum Component: Incidence of Confirmed Infant HIV InfectionTime frame: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
- Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse EventsTime frame: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
- Maternal Health Component: Incidence of Progression to AIDS-defining Illness or DeathTime frame: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, Maharashtra, India
Blantyre CRS
Blantyre, Malawi
Malawi CRS
Lilongwe, Malawi
Soweto IMPAACT CRS
Johannesburg, Gauteng, South Africa
Shandukani Research CRS
Johannesburg, Gauteng, South Africa
Durban Paediatric HIV CRS
Durban, KwaZulu-Natal, South Africa
Umlazi CRS
Durban, KwaZulu-Natal, South Africa
Family Clinical Research Unit (FAM-CRU) CRS
Cape Town, Western Cape, South Africa
Kilimanjaro Christian Medical Centre (KCMC)
Moshi, Tanzania
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
Kampala, Uganda
George CRS
Lusaka, Zambia
Seke North CRS
Chitungwiza, Zimbabwe
St Mary's CRS
Chitungwiza, Zimbabwe
Harare Family Care CRS
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.